Pfizer announced Saturday that tweaking its COVID-19 vaccine to better target the Omicron variant is safe and works — just days before regulators debate whether to offer Americans updated booster ...

In a recent study published in the Emerging Infectious Disease journal, researchers compared the neutralization associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron ...

Add Yahoo as a preferred source to see more of our stories on Google. On Tuesday, an advisory panel of the Food and Drug Administration met to discuss what the next generation of COVID-19 boosters ...

With the rise of omicron came the fall of long-lasting protection from reinfection with the pandemic coronavirus SARS-CoV-2, according to a study published in Nature. Using population-wide data from ...

Pfizer's and Moderna's omicron boosters reduced the risk of mild illness from the XBB family of subvariants compared to people who did not receive the shot, according to a study from the Centers for ...

On Tuesday, an advisory panel of the Food and Drug Administration met to discuss what the next generation of COVID-19 boosters might look like this fall. And Thursday the panel agreed they should ...

In a recent study posted to the medRxiv* preprint server, researchers from Sweden conducted a cohort study to evaluate the protection granted by previous severe acute respiratory syndrome coronavirus ...

The CDC has published real-world data showing the omicron booster cuts the risk of mid illness from the fast spreading XBB subvariants. But the protection varies by age. Adults ages 18 to 49 had a 48% ...